The presence of T cell epitopes is important for induction of antibody responses against antigens directed to DEC205+ dendritic cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Amorim, Kelly N S ^a   Rampazo, Eline V ^a   Antonialli, Renan ^a   Yamamoto, Marcio M ^a   Rodrigues, Mauricio M ^b,c   Soares, Irene S ^a,c   Boscardin, Silvia B ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c National Institute of Science and Technology in Tropical Diseases   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; FUSION PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; LECTIN; MEROZOITE SURFACE PROTEIN 1; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DEFICIENCY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHYSIOLOGY; SPLEEN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CD4 ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LECTINS, C-TYPE; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85007010450     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39250     Document Type: Article

References (46)

1. Steinman, R. M. & Hemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311, 17-58 (2006).
2. MacLennan, I. & Vinuesa, C. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 17, 235-238, doi: S1074761302003989 (2002).
3. Lahoud, M. H. et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol 187, 842-850, doi: 10.4049/jimmunol.1101176 (2011).
4. Caminschi, I. et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112, 3264-3273, doi: 10.1182/blood-2008-05-155176 (2008).
5. Boscardin, S. B. et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203, 599-606, doi: 10.1084/jem.20051639 (2006).
6. + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 203, 607-617 (2006).
7. Idoyaga, J. et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 108, 2384-2389, doi: 10.1073/pnas.1019547108 (2011).
8. Steinman, R. M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319-324, doi: 10.1016/j. immuni.2008.08.001 (2008).
9. Inaba, K. et al. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 163, 148-156, doi: S0008874985711094 [pii] (1995).
10. Witmer-Pack, M. D., Swiggard, W. J., Mirza, A., Inaba, K. & Steinman, R. M. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell Immunol 163, 157-162, doi: 10.1006/cimm.1995.1110 (1995).
11. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194, 769-779 (2001).
12. + T cell tolerance. J Exp Med 196, 1627-1638 (2002).
13. Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199, 815-824 (2004).
14. Henriques, H. R. et al. Targeting the Non-structural Protein 1 from Dengue Virus to a Dendritic Cell Population Confers Protective Immunity to Lethal Virus Challenge. PLoS Negl Trop Dis 7, e2330, doi: 10.1371/journal.pntd.0002330 (2013).
15. + T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105, 2574-2579, doi: 10.1073/pnas.0711976105 (2008).
16. + T cell proliferation. PLoS One 3, e2404, doi: 10.1371/journal.pone.0002404 (2008).
17. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007).
18. + T cell immunity to mouse survivin. J Immunol 177, 8410-8421, doi: 177/12/8410 (2006).
19. Wang, B. et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 14, R39, doi: 10.1186/bcr3135 (2012).
20. + T cell responses with broad antigen specificity. J Immunol 186, 1218-1227, doi: 10.4049/jimmunol.1000808 (2011).
21. Mahnke, K. et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 65, 7007-7012, doi: 10.1158/0008-5472.CAN-05-0938 (2005).
22. Do, Y. et al. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Eur J Immunol 40, 2791-2796, doi: 10.1002/eji.201040511 (2010).
23. Do, Y. et al. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol 38, 20-29, doi: 10.1002/eji.200737799 (2008).
24. + T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28, 7256-7266, doi: 10.1016/j. vaccine.2010.08.098 (2010).
25. Han, H. J. et al. Epidermal growth factor-like motifs 1 and 2 of Plasmodium vivax merozoite surface protein 1 are critical domains in erythrocyte invasion. Biochem Biophys Res Commun 320, 563-570, doi: 10.1016/j.bbrc.2004.06.008 (2004).
26. Blackman, M. J., Ling, I. T., Nicholls, S. C. & Holder, A. A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 49, 29-33, doi: 0166-6851(91)90127-R (1991).
27. Blackman, M. J., Heidrich, H. G., Donachie, S., McBride, J. S. & Holder, A. A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172, 379-382 (1990).
28. Soares, I. S., Levitus, G., Souza, J. M., Del Portillo, H. A. & Rodrigues, M. M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65, 1606-1614 (1997).
29. Soares, I. S. et al. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg 60, 357-363 (1999).
30. Wilson, D. W. et al. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS One 6, e27705, doi: 10.1371/journal.pone.0027705 (2011).
31. Udhayakumar, V. et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 154, 6022-6030 (1995).
32. Hui, G. & Hashimoto, C. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 25, 948-956, doi: 10.1016/j.vaccine.2006.08.041 (2007).
33. Draper, S. J. et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 5, 95-105, doi: 10.1016/j.chom.2008.12.004 (2009).
34. Daly, T. M. & Long, C. A. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun 61, 2462-2467 (1993).
35. Daly, T. M. & Long, C. A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155, 236-243 (1995).
36. Shi, Y. P. et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 64, 2716-2723 (1996).
37. + T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect 8, 2130-2137, doi: 10.1016/j.micinf.2006.03.012 (2006).
38. Blackman, M. J. & Holder, A. A. Use of a recombinant baculovirus product to measure naturally-acquired human antibodies to disulphide-constrained epitopes on the P. falciparum merozoite surface protein-1 (MSP1). FEMS Immunol Med Microbiol 6, 307-315 (1993).
39. + Th1 immunity with poly IC as adjuvant. J Exp Med 206, 1589-1602, doi: 10.1084/jem.20090247 (2009).
40. Egan, A. F., Burghaus, P., Druilhe, P., Holder, A. A. & Riley, E. M. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21, 133-139 (1999).
41. Stavnezer, J. Molecular processes that regulate class switching. Curr Top Microbiol Immunol 245, 127-168 (2000).
42. Putaporntip, C. et al. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA 99, 16348-16353, doi: 10.1073/pnas.252348999 (2002).
43. Cunha, M. G., Rodrigues, M. M. & Soares, I. S. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors. Vaccine 20, 385-396, doi: S0264410X01003590 (2001).
44. Zompi, S., Santich, B. H., Beatty, P. R. & Harris, E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 188, 404-416, doi: 10.4049/jimmunol.1102124 (2012).
45. de Souza, V. A. et al. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. J Clin Microbiol 42, 1782-1784 (2004).
46. Ribeiro, S. P. et al. A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 5, e11072, doi: 10.1371/journal.pone.0011072 (2010).